Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Somatic mutations driving aldosterone production have been identified in approximately 90% of aldosterone-producing adenomas (APAs) using an aldosterone synthase (CYP11B2) immunohistochemistry (IHC)-guided DNA sequencing approach. In the present study, using CYP11B2-guided whole-exome sequencing (WES) and targeted amplicon sequencing, we detected 2 somatic variants in in 2 APAs that were negative for currently known aldosterone-driver mutations. The gene encodes the voltage-gated chloride channel ClC-2. germline variants have previously been shown to cause familial hyperaldosteronism type II. Somatic mutations in were identified in 2 of 115 APAs, resulting in a prevalence of 1.74%. One of the somatic mutations (c.G71A,p.G24D) was identical to a previously described germline variant causing early-onset PA, but was present only as a somatic mutation. The second mutation, which affects the same region of the gene, has not been reported previously (c.64-2_74del). These findings prove that WES of CYP11B2-guided mutation-negative APAs can help determine rarer genetic causes of sporadic PA.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7528565PMC
http://dx.doi.org/10.1210/jendso/bvaa123DOI Listing

Publication Analysis

Top Keywords

somatic mutations
16
aldosterone-producing adenomas
8
mutations
5
somatic
5
identification somatic
4
mutations aldosterone-producing
4
adenomas somatic
4
mutations driving
4
driving aldosterone
4
aldosterone production
4

Similar Publications

Introduction Neuroendocrine tumors (NETs) are a rare and heterogeneous group of neoplasms with both clinical and genetic diversity. The clinical applicability of molecular profiling using liquid biopsy for identifying actionable drug targets and prognostic indicators in patients with advanced NETs remains unclear. Methods In this study, we utilized a custom-made 37 genes panel of circulating tumor DNA (ctDNA) based on next-generation sequencing (NGS) in 47 patients with advanced NETs.

View Article and Find Full Text PDF

Background: Turner syndrome (TS), also known as congenital ovarian hypoplasia, is one of the most common sex chromosome diseases in women. It is caused by the complete or partial deletion or structural change of one X chromosome in all or part of somatic cells. A rare case of karyotype Turner syndrome is reported.

View Article and Find Full Text PDF

STN1 Shields CTC1 From TRIM32-Mediated Ubiquitination to Prevent Cellular Aging.

Aging Cell

September 2025

Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China.

The CST (CTC1-STN1-TEN1) complex, a single-stranded DNA (ssDNA) binding complex, is essential for telomere maintenance and genome stability. Depletion of either CTC1 or STN1 results in cellular senescence, while mutations in these components are associated with severe hereditary disorders. In this study, we demonstrate that the direct STN1-CTC1 interaction stabilizes CTC1 by preventing its degradation via TRIM32 mediated ubiquitination.

View Article and Find Full Text PDF

Background: Clonotyping of immunoglobulin heavy chain (IGH) gene rearrangements is critical for diagnosis, prognostication, and measurable residual disease monitoring in chronic lymphocytic leukemia (CLL). Although short-read next-generation sequencing (NGS) platforms, such as Illumina MiSeq, are widely used, they face challenges in spanning full VDJ rearrangements. Long-read sequencing via Oxford Nanopore Technologies (ONT) offers a potential alternative using the compact and cost-effective flow cells.

View Article and Find Full Text PDF

Somatic mutations in several genes, including key oncogenes and tumour suppressor genes, are present from early life and can accumulate as an individual ages, indicating that the potential for cancer is present and growing throughout life. However, the risk of developing cancer rises sharply after 50-60 years of age, suggesting that the ability of these mutations to undergo clonal expansion and drive cancer development is dependent on the progressive changes in the epigenome and microenvironment that occur during ageing. Epigenetic changes, including DNA methylation and histone modifications, can drive various hallmarks of ageing in precancerous cells, including induction of senescence, the senescence-associated secretory phenotype, genomic instability and reduction of nuclear integrity, metabolic and inflammatory stress responses, stem cell function and differentiation potential, and redox balance.

View Article and Find Full Text PDF